Shots:
- Intract to receive an up front, development & commercial milestone along with royalties on product sales. Bio-Thera gets global license to Intract’s Soteria & Phloral oral drug delivery platform to develop a mAb product for chronic GI inflammatory diseases
- Intract will be responsible for preclinical research of the product while Bio-Thera will get an option to expand the development of the product for multiple GI indications & will lead the manufacturing & commercialization of any approved products
- Intract’s Soteria protects proteins such as mAbs from degradation in intestinal lumen whereas Phloral utilizes pH & enzymes produced by colonic bacteria to allow payloads in the colon
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Bio-Thera Signs a License Agreement with Intract for Soteria and Phloral Technologies to Develop Oral Antibody Therapies first appeared on PharmaShots.
